| Abstrakt: |
Introduction: Psoriasis, a persistent ailment, significantly influences the day-to-day existence of individuals, particularly in the context of their interpersonal relationships. The purpose of this study is to elucidate how depression affects the quality of life for individuals dealing with moderate psoriasis. Methods: A cross-sectional investigation was undertaken involving 16 psoriasis patients during the period spanning April to May 2023. Patients with psoriasis vulgaris completed self-administered questionnaires which included demographic characteristics, Hamilton Depression Rating Scale (HAM-D), and Dermatological Life Quality Index (DLQI). Data were collected both physically, during periodic checks, and online by email. Only 16 patients met the eligibility criteria for study entry. All patients included in the study had moderate psoriasis vulgaris. Exclusion criteria for participation in the study were current psychotropic medication use. severe comorbidities or chronic medical conditions and visual, auditory, linguistic, or cognitive impairments. Results: Upon completion of the Hamilton Depression Rating Scale (HAM-D), half of the participants (50%) exhibited a score below 8, signifying minimal depression, while the remaining half (50%) scored between 8-16, indicative of mild depression. Notably, 87.5% of the participants registered a Dermatological Life Quality Index (DLQI) score exceeding 10, highlighting severe impairment in their quality of life. The findings revealed a positive correlation between the DLQI and HAM-D, emphasizing a connection between dermatological and depressive factors. In conclusion, the study underscores the substantial impact of depressive symptoms on the quality of life among analyzed psoriasis patients. It advocates for a holistic, multidisciplinary approach in the treatment of psoriasis patients, recognizing the need to address not only the disease itself but also the overall well-being of the patient. [ABSTRACT FROM AUTHOR] |
